186 related articles for article (PubMed ID: 27256098)
1. Expression of Somatostatin Receptor Type 2A and PTEN in Neuroendocrine Neoplasms Is Associated with Tumor Grade but Not with Site of Origin.
Wada H; Matsuda K; Akazawa Y; Yamaguchi Y; Miura S; Ueki N; Kinoshita A; Yoshiura K; Kondo H; Ito M; Nagayasu T; Nakashima M
Endocr Pathol; 2016 Sep; 27(3):179-87. PubMed ID: 27256098
[TBL] [Abstract][Full Text] [Related]
2. Long Non-coding RNAs in Pulmonary Neuroendocrine Neoplasms.
Narayanan D; Mandal R; Hardin H; Chanana V; Schwalbe M; Rosenbaum J; Buehler D; Lloyd RV
Endocr Pathol; 2020 Sep; 31(3):254-263. PubMed ID: 32388776
[TBL] [Abstract][Full Text] [Related]
3. Lung neuroendocrine tumors: correlation of ubiquitinylation and sumoylation with nucleo-cytosolic partitioning of PTEN.
Collaud S; Tischler V; Atanassoff A; Wiedl T; Komminoth P; Oehlschlegel C; Weder W; Soltermann A
BMC Cancer; 2015 Feb; 15():74. PubMed ID: 25884169
[TBL] [Abstract][Full Text] [Related]
4. Analysis of somatostatin receptor 2A immunohistochemistry, RT-qPCR, and in vivo PET/CT data in patients with pancreatic neuroendocrine neoplasm.
Kaemmerer D; Wirtz RM; Fischer EK; Hommann M; Sänger J; Prasad V; Specht E; Baum RP; Schulz S; Lupp A
Pancreas; 2015 May; 44(4):648-54. PubMed ID: 25872131
[TBL] [Abstract][Full Text] [Related]
5. Gene expression of somatostatin receptor subtypes SSTR2a, SSTR3 and SSTR5 in peripheral blood of neuroendocrine lung cancer affected patients.
Muscarella LA; D'Alessandro V; la Torre A; Copetti M; De Cata A; Parrella P; Sperandeo M; Pellegrini F; Frusciante V; Maiello E; Merla G; Fazio VM; Vendemiale G
Cell Oncol (Dordr); 2011 Oct; 34(5):435-41. PubMed ID: 21503779
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome.
Kiviniemi A; Gardberg M; Kivinen K; Posti JP; Vuorinen V; Sipilä J; Rahi M; Sankinen M; Minn H
Oncotarget; 2017 Jul; 8(30):49123-49132. PubMed ID: 28467778
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors.
Kimura N; Pilichowska M; Date F; Kimura I; Schindler M
Clin Cancer Res; 1999 Nov; 5(11):3483-7. PubMed ID: 10589762
[TBL] [Abstract][Full Text] [Related]
8. In liver metastases from small intestinal neuroendocrine tumors, SSTR2A expression is heterogeneous.
Charoenpitakchai M; Liu E; Zhao Z; Koyama T; Huh WJ; Berlin J; Hande K; Walker R; Shi C
Virchows Arch; 2017 May; 470(5):545-552. PubMed ID: 28213807
[TBL] [Abstract][Full Text] [Related]
9. Follicular dendritic cell sarcoma: clinicopathologic study of 15 cases with emphasis on novel expression of MDM2, somatostatin receptor 2A, and PD-L1.
Agaimy A; Michal M; Hadravsky L; Michal M
Ann Diagn Pathol; 2016 Aug; 23():21-8. PubMed ID: 27402219
[TBL] [Abstract][Full Text] [Related]
10. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine carcinoma of uterine cervix.
Kajiwara H; Hirabayashi K; Miyazawa M; Nakamura N; Hirasawa T; Muramatsu T; Mikami M; Yasuda M; Osamura RY
Arch Gynecol Obstet; 2009 Apr; 279(4):521-5. PubMed ID: 18726606
[TBL] [Abstract][Full Text] [Related]
12. Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy.
Kaemmerer D; Träger T; Hoffmeister M; Sipos B; Hommann M; Sänger J; Schulz S; Lupp A
Oncotarget; 2015 Sep; 6(29):27566-79. PubMed ID: 26259237
[TBL] [Abstract][Full Text] [Related]
13. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS
J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652
[TBL] [Abstract][Full Text] [Related]
14. Single institutional experience on primary neuroendocrine neoplasms of the kidney: a rare distinct entity.
Amin M; Trikalinos N; Chatterjee D
Hum Pathol; 2021 Aug; 114():36-43. PubMed ID: 33891968
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores.
Diakatou E; Alexandraki KI; Tsolakis AV; Kontogeorgos G; Chatzellis E; Leonti A; Kaltsas GA
Clin Endocrinol (Oxf); 2015 Sep; 83(3):420-8. PubMed ID: 25808161
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine neoplasms and somatostatin receptor subtypes expression.
Hankus J; Tomaszewska R
Nucl Med Rev Cent East Eur; 2016; 19(2):111-7. PubMed ID: 27479788
[TBL] [Abstract][Full Text] [Related]
17. Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.
Pusceddu S; De Braud F; Festinese F; Bregant C; Lorenzoni A; Maccauro M; Milione M; Concas L; Formisano B; Leuzzi L; Mazzaferro V; Buzzoni R
Future Oncol; 2015; 11(13):1947-59. PubMed ID: 26161929
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers.
Kaemmerer D; Specht E; Sänger J; Wirtz RM; Sayeg M; Schulz S; Lupp A
J Clin Endocrinol Metab; 2015 Mar; 100(3):831-40. PubMed ID: 25494861
[TBL] [Abstract][Full Text] [Related]
19. Frequent expression of somatostatin receptor 2a in olfactory neuroblastomas: a new and distinctive feature.
Czapiewski P; Kunc M; Gorczyński A; Haybaeck J; Okoń K; Reszec J; Lewczuk A; Dzierzanowski J; Karczewska J; Biernat W; Turri-Zanoni M; Castelnuovo P; Taverna C; Franchi A; La Rosa S; Sessa F; Klöppel G
Hum Pathol; 2018 Sep; 79():144-150. PubMed ID: 29807052
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20.
Konukiewitz B; Schlitter AM; Jesinghaus M; Pfister D; Steiger K; Segler A; Agaimy A; Sipos B; Zamboni G; Weichert W; Esposito I; Pfarr N; Klöppel G
Mod Pathol; 2017 Apr; 30(4):587-598. PubMed ID: 28059098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
